These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21352854)

  • 41. TLR Function in Murine CD4(+) T Lymphocytes and Their Role in Inflammation.
    Flaherty S; Reynolds JM
    Methods Mol Biol; 2016; 1390():215-27. PubMed ID: 26803632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.
    Asprodites N; Zheng L; Geng D; Velasco-Gonzalez C; Sanchez-Perez L; Davila E
    FASEB J; 2008 Oct; 22(10):3628-37. PubMed ID: 18587008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toll-like receptors in lymphoid malignancies: double-edged sword.
    Harsini S; Beigy M; Akhavan-Sabbagh M; Rezaei N
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):262-83. PubMed ID: 24051205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toll-like receptor agonists in cancer therapy.
    Adams S
    Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention.
    Zou H; Wang WK; Liu YL; Braddock M; Zheng MH; Huang DS
    Expert Opin Ther Targets; 2016 Sep; 20(9):1127-35. PubMed ID: 26998881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Harnessing the Microbiome to Enhance Cancer Immunotherapy.
    Nelson MH; Diven MA; Huff LW; Paulos CM
    J Immunol Res; 2015; 2015():368736. PubMed ID: 26101781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
    Lee SN; Jin SM; Shin HS; Lim YT
    Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil.
    Patchett AL; Latham R; Brettingham-Moore KH; Tovar C; Lyons AB; Woods GM
    Dev Comp Immunol; 2015 Nov; 53(1):123-33. PubMed ID: 26182986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.
    Payne KK; Bear HD; Manjili MH
    Future Oncol; 2014 Aug; 10(10):1779-94. PubMed ID: 25303057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The contribution of direct TLR signaling to T cell responses.
    Rahman AH; Taylor DK; Turka LA
    Immunol Res; 2009; 45(1):25-36. PubMed ID: 19597998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.
    Dajon M; Iribarren K; Cremer I
    Immunobiology; 2017 Jan; 222(1):89-100. PubMed ID: 27349597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toll-like receptor agonists: a patent review (2011 - 2013).
    Hussein WM; Liu TY; Skwarczynski M; Toth I
    Expert Opin Ther Pat; 2014 Apr; 24(4):453-70. PubMed ID: 24456079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells.
    Nouri Y; Weinkove R; Perret R
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
    Mikulandra M; Pavelic J; Glavan TM
    Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.
    Wittig B; Schmidt M; Scheithauer W; Schmoll HJ
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):31-44. PubMed ID: 25577571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TLR Agonists as Adjuvants for Cancer Vaccines.
    Li JK; Balic JJ; Yu L; Jenkins B
    Adv Exp Med Biol; 2017; 1024():195-212. PubMed ID: 28921471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting toll-like receptors on T cells as a therapeutic strategy against tumors.
    Ding R; Jiao A; Zhang B
    Int Immunopharmacol; 2022 Jun; 107():108708. PubMed ID: 35306281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis.
    Tian Y; Huang B; Li J; Tian X; Zeng X
    Front Immunol; 2021; 12():792901. PubMed ID: 35126357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triggering TLR signaling in vaccination.
    van Duin D; Medzhitov R; Shaw AC
    Trends Immunol; 2006 Jan; 27(1):49-55. PubMed ID: 16310411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions.
    Yu L; Wang L; Chen S
    Biochim Biophys Acta; 2013 Apr; 1835(2):144-54. PubMed ID: 23232186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.